Freetown
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 8 / 9.3 / 85.9 / (37.0-169.3) / Male / 4 / 6.3 / nc / (nc-nc)
Female / 3 / 2.6 / nc / (nc-nc) / Female / 3 / 4.3 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 2 / 2.0 / nc / (nc-nc) / Male / 3 / 2.0 / nc / (nc-nc)
Female / 1 / 1.4 / nc / (nc-nc) / Female / 2 / 1.2 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.3 / nc / (nc-nc) / Male / 5 / 5.6 / 88.6 / (28.5-206.6)
Female / 41 / 34.5 / 118.8 / (85.2-161.2) / Female / 7 / 3.9 / 180.3 / (72.2-371.5)
Cervix Uteri / Oral Cavity & Pharynx
Male / 5 / 4.9 / 101.5 / (32.7-236.9)
Female / 3 / 1.3 / nc / (nc-nc) / Female / 4 / 1.7 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 10 / 10.4 / 95.8 / (45.9-176.2)
Female / 6 / 7.9 / 75.8 / (27.7-164.9) / Female / 3 / 2.9 / nc / (nc-nc)
Esophagus / Pancreas
Male / 1 / 2.7 / nc / (nc-nc) / Male / 0 / 3.4 / nc / (nc-nc)
Female / 0 / 0.5 / nc / (nc-nc) / Female / 4 / 2.5 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 1 / 0.8 / nc / (nc-nc) / Male / 45 / 35.7 / 126.1 / (92.0-168.8)
Female / 0 / 0.5 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 6 / 5.7 / 105.7 / (38.6-230.0) / Male / 3 / 2.3 / nc / (nc-nc)
Female / 2 / 2.6 / nc / (nc-nc) / Female / 1 / 1.0 / nc / (nc-nc)
Larynx / Testis
Male / 2 / 1.6 / nc / (nc-nc) / Male / 0 / 1.4 / nc / (nc-nc)
Female / 0 / 0.4 / nc / (nc-nc)
Leukemia / Thyroid
Male / 2 / 3.9 / nc / (nc-nc) / Male / 2 / 2.7 / nc / (nc-nc)
Female / 1 / 2.2 / nc / (nc-nc) / Female / 6 / 7.0 / 85.4 / (31.2-185.9)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 1 / 3.6 / nc / (nc-nc)
Female / 1 / 0.9 / nc / (nc-nc) / Female / 11 / 7.9 / 139.5 / (69.5-249.6)
Lung and Bronchus / All Sites / Types
Male / 19 / 17.3 / 110.1 / (66.2-171.9) / Male / 130 / 131.4 / 98.9 / (82.6-117.5)
Female / 25 / 14.4 / 174.2 / (112.7-257.1) / Female / 137 / 109.5 / 125.1 / (105.0-147.9)
Obs = observed case count; Exp = expected case count;
SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability;
nc = The SIR and 95% CI were not calculated when Obs < 5;
112
Gardner
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 20 / 22.1 / 90.5 / (55.3-139.8) / Male / 6 / 14.3 / 41.9 / (15.3-91.1)
Female / 9 / 8.5 / 105.4 / (48.1-200.0) / Female / 7 / 11.3 / 62.0 / (24.8-127.7)
Brain and Other Nervous System / Multiple Myeloma
Male / 2 / 4.3 / nc / (nc-nc) / Male / 3 / 4.5 / nc / (nc-nc)
Female / 6 / 3.5 / 171.1 / (62.5-372.3) / Female / 3 / 3.8 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 1 / 0.7 / nc / (nc-nc) / Male / 9 / 12.9 / 69.9 / (31.9-132.8)
Female / 72 / 85.7 / 84.0 / (65.7-105.8) / Female / 13 / 11.5 / 112.9 / (60.1-193.1)
Cervix Uteri / Oral Cavity & Pharynx
Male / 12 / 10.2 / 117.1 / (60.4-204.5)
Female / 0 / 2.9 / nc / (nc-nc) / Female / 4 / 4.7 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 24 / 24.2 / 99.3 / (63.6-147.8)
Female / 26 / 25.7 / 101.1 / (66.0-148.2) / Female / 7 / 7.7 / 90.4 / (36.2-186.3)
Esophagus / Pancreas
Male / 10 / 5.8 / 172.3 / (82.5-316.9) / Male / 8 / 7.7 / 103.7 / (44.7-204.4)
Female / 2 / 1.6 / nc / (nc-nc) / Female / 8 / 8.7 / 92.1 / (39.7-181.5)
Hodgkin Lymphoma / Prostate
Male / 1 / 1.8 / nc / (nc-nc) / Male / 67 / 71.4 / 93.8 / (72.7-119.1)
Female / 2 / 1.4 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 17 / 12.1 / 140.8 / (82.0-225.4) / Male / 2 / 5.2 / nc / (nc-nc)
Female / 8 / 7.0 / 114.3 / (49.2-225.2) / Female / 5 / 3.4 / 149.1 / (48.0-347.9)
Larynx / Testis
Male / 2 / 3.3 / nc / (nc-nc) / Male / 3 / 3.3 / nc / (nc-nc)
Female / 0 / 1.0 / nc / (nc-nc)
Leukemia / Thyroid
Male / 11 / 8.9 / 123.2 / (61.4-220.4) / Male / 2 / 5.7 / nc / (nc-nc)
Female / 11 / 6.8 / 160.6 / (80.1-287.5) / Female / 12 / 15.3 / 78.3 / (40.4-136.9)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 10 / 7.7 / 130.6 / (62.5-240.2)
Female / 3 / 2.6 / nc / (nc-nc) / Female / 22 / 19.3 / 114.1 / (71.5-172.8)
Lung and Bronchus / All Sites / Types
Male / 53 / 38.9 / 136.3 / (102.1-178.3) / Male / 285 / 288.2 / 98.9 / (87.7-111.1)
Female / 49 / 43.0 / 113.8 / (84.2-150.5) / Female / 299 / 301.1 / 99.3 / (88.4-111.2)
Obs = observed case count; Exp = expected case count;
SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability;
nc = The SIR and 95% CI were not calculated when Obs < 5;
113
Georgetown
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 2 / 8.8 / nc / (nc-nc) / Male / 8 / 5.8 / 136.8 / (58.9-269.5)
Female / 1 / 2.8 / nc / (nc-nc) / Female / 5 / 4.3 / 115.4 / (37.2-269.2)
Brain and Other Nervous System / Multiple Myeloma
Male / 0 / 1.8 / nc / (nc-nc) / Male / 0 / 1.8 / nc / (nc-nc)
Female / 2 / 1.4 / nc / (nc-nc) / Female / 3 / 1.3 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.3 / nc / (nc-nc) / Male / 9 / 5.2 / 172.2 / (78.6-327.0)
Female / 33 / 35.7 / 92.5 / (63.7-129.9) / Female / 2 / 4.1 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 1 / 4.4 / nc / (nc-nc)
Female / 1 / 1.2 / nc / (nc-nc) / Female / 0 / 1.8 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 6 / 9.8 / 61.1 / (22.3-132.9)
Female / 7 / 8.4 / 83.6 / (33.5-172.3) / Female / 0 / 3.1 / nc / (nc-nc)
Esophagus / Pancreas
Male / 3 / 2.4 / nc / (nc-nc) / Male / 2 / 3.2 / nc / (nc-nc)
Female / 1 / 0.5 / nc / (nc-nc) / Female / 3 / 2.7 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 0 / 0.6 / nc / (nc-nc) / Male / 36 / 32.1 / 112.3 / (78.6-155.5)
Female / 0 / 0.5 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 7 / 5.2 / 134.0 / (53.7-276.2) / Male / 2 / 2.1 / nc / (nc-nc)
Female / 2 / 2.7 / nc / (nc-nc) / Female / 1 / 1.0 / nc / (nc-nc)
Larynx / Testis
Male / 0 / 1.4 / nc / (nc-nc) / Male / 3 / 1.1 / nc / (nc-nc)
Female / 1 / 0.4 / nc / (nc-nc)
Leukemia / Thyroid
Male / 2 / 3.6 / nc / (nc-nc) / Male / 3 / 2.4 / nc / (nc-nc)
Female / 1 / 2.3 / nc / (nc-nc) / Female / 5 / 6.7 / 74.7 / (24.1-174.2)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 2 / 3.2 / nc / (nc-nc)
Female / 1 / 0.9 / nc / (nc-nc) / Female / 12 / 8.3 / 144.5 / (74.6-252.5)
Lung and Bronchus / All Sites / Types
Male / 7 / 16.3 / 43.1 / (17.3-88.7) / Male / 101 / 120.6 / 83.7 / (68.2-101.8)
Female / 20 / 15.6 / 127.8 / (78.0-197.4) / Female / 114 / 114.1 / 99.9 / (82.4-120.0)
Obs = observed case count; Exp = expected case count;
SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability;
nc = The SIR and 95% CI were not calculated when Obs < 5;
114
Gill
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 3 / 1.8 / nc / (nc-nc) / Male / 0 / 1.2 / nc / (nc-nc)
Female / 0 / 0.6 / nc / (nc-nc) / Female / 1 / 0.9 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 2 / 0.4 / nc / (nc-nc) / Male / 0 / 0.4 / nc / (nc-nc)
Female / 0 / 0.3 / nc / (nc-nc) / Female / 0 / 0.3 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.1 / nc / (nc-nc) / Male / 0 / 1.1 / nc / (nc-nc)
Female / 8 / 7.3 / 109.9 / (47.3-216.6) / Female / 0 / 0.8 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 0 / 1.0 / nc / (nc-nc)
Female / 1 / 0.2 / nc / (nc-nc) / Female / 2 / 0.4 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 1 / 2.1 / nc / (nc-nc)
Female / 3 / 1.7 / nc / (nc-nc) / Female / 1 / 0.6 / nc / (nc-nc)
Esophagus / Pancreas
Male / 0 / 0.5 / nc / (nc-nc) / Male / 0 / 0.7 / nc / (nc-nc)
Female / 1 / 0.1 / nc / (nc-nc) / Female / 2 / 0.6 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 1 / 0.1 / nc / (nc-nc) / Male / 9 / 7.6 / 117.8 / (53.8-223.7)
Female / 0 / 0.1 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 0 / 1.1 / nc / (nc-nc) / Male / 0 / 0.4 / nc / (nc-nc)
Female / 1 / 0.6 / nc / (nc-nc) / Female / 0 / 0.2 / nc / (nc-nc)
Larynx / Testis
Male / 0 / 0.3 / nc / (nc-nc) / Male / 0 / 0.2 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc)
Leukemia / Thyroid
Male / 1 / 0.7 / nc / (nc-nc) / Male / 0 / 0.5 / nc / (nc-nc)
Female / 0 / 0.5 / nc / (nc-nc) / Female / 0 / 1.3 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 1 / 0.8 / nc / (nc-nc)
Female / 0 / 0.2 / nc / (nc-nc) / Female / 1 / 1.8 / nc / (nc-nc)
Lung and Bronchus / All Sites / Types
Male / 7 / 3.4 / 205.3 / (82.2-423.0) / Male / 26 / 26.3 / 98.8 / (64.5-144.8)
Female / 6 / 3.2 / 189.6 / (69.2-412.6) / Female / 28 / 23.4 / 119.7 / (79.5-173.1)
Obs = observed case count; Exp = expected case count;
SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability;
nc = The SIR and 95% CI were not calculated when Obs < 5;
115
Gloucester
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 42 / 39.0 / 107.8 / (77.7-145.7) / Male / 29 / 24.4 / 118.7 / (79.5-170.5)
Female / 23 / 14.7 / 156.8 / (99.3-235.3) / Female / 23 / 19.4 / 118.8 / (75.3-178.3)
Brain and Other Nervous System / Multiple Myeloma
Male / 4 / 6.9 / nc / (nc-nc) / Male / 9 / 7.8 / 114.9 / (52.4-218.1)
Female / 5 / 5.9 / 84.2 / (27.1-196.4) / Female / 2 / 6.6 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 1 / 1.4 / nc / (nc-nc) / Male / 24 / 21.7 / 110.4 / (70.7-164.3)
Female / 168 / 157.5 / 106.6 / (91.1-124.0) / Female / 21 / 20.1 / 104.7 / (64.8-160.1)
Cervix Uteri / Oral Cavity & Pharynx
Male / 21 / 18.0 / 116.8 / (72.3-178.6)
Female / 3 / 4.9 / nc / (nc-nc) / Female / 11 / 8.5 / 129.9 / (64.7-232.4)
Colon / Rectum / Ovary
Male / 43 / 40.7 / 105.7 / (76.5-142.3)
Female / 35 / 43.1 / 81.3 / (56.6-113.0) / Female / 18 / 14.0 / 128.9 / (76.3-203.7)
Esophagus / Pancreas
Male / 15 / 10.6 / 141.4 / (79.1-233.2) / Male / 22 / 13.8 / 159.1 / (99.7-241.0)
Female / 2 / 2.8 / nc / (nc-nc) / Female / 12 / 14.6 / 82.2 / (42.4-143.6)
Hodgkin Lymphoma / Prostate
Male / 4 / 2.4 / nc / (nc-nc) / Male / 141 / 140.9 / 100.1 / (84.2-118.0)
Female / 4 / 2.0 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 16 / 21.3 / 75.3 / (43.0-122.2) / Male / 10 / 9.1 / 110.1 / (52.7-202.5)
Female / 17 / 12.6 / 134.5 / (78.3-215.3) / Female / 2 / 5.5 / nc / (nc-nc)
Larynx / Testis
Male / 8 / 6.3 / 127.7 / (55.0-251.7) / Male / 4 / 3.8 / nc / (nc-nc)
Female / 3 / 1.9 / nc / (nc-nc)
Leukemia / Thyroid
Male / 21 / 14.9 / 141.3 / (87.4-216.0) / Male / 10 / 8.9 / 112.7 / (53.9-207.2)
Female / 9 / 11.3 / 79.8 / (36.4-151.5) / Female / 33 / 25.9 / 127.6 / (87.8-179.2)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 10 / 13.4 / 74.4 / (35.6-136.8)
Female / 6 / 4.7 / 128.7 / (47.0-280.0) / Female / 28 / 36.9 / 75.8 / (50.4-109.6)
Lung and Bronchus / All Sites / Types
Male / 87 / 71.1 / 122.4 / (98.0-151.0) / Male / 565 / 514.6 / 109.8 / (100.9-119.2)
Female / 100 / 78.3 / 127.6 / (103.8-155.2) / Female / 562 / 533.9 / 105.3 / (96.7-114.3)
Obs = observed case count; Exp = expected case count;
SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability;
nc = The SIR and 95% CI were not calculated when Obs < 5;
116
Goshen
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 2 / 1.2 / nc / (nc-nc) / Male / 1 / 0.8 / nc / (nc-nc)
Female / 0 / 0.5 / nc / (nc-nc) / Female / 0 / 0.7 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 0 / 0.2 / nc / (nc-nc) / Male / 0 / 0.2 / nc / (nc-nc)
Female / 0 / 0.2 / nc / (nc-nc) / Female / 0 / 0.2 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.0 / nc / (nc-nc) / Male / 3 / 0.7 / nc / (nc-nc)
Female / 3 / 5.6 / nc / (nc-nc) / Female / 0 / 0.7 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 1 / 0.6 / nc / (nc-nc)
Female / 0 / 0.2 / nc / (nc-nc) / Female / 0 / 0.3 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 0 / 1.3 / nc / (nc-nc)
Female / 0 / 1.4 / nc / (nc-nc) / Female / 0 / 0.5 / nc / (nc-nc)
Esophagus / Pancreas
Male / 0 / 0.3 / nc / (nc-nc) / Male / 0 / 0.4 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 0 / 0.5 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 0 / 0.1 / nc / (nc-nc) / Male / 3 / 4.3 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 0 / 0.7 / nc / (nc-nc) / Male / 0 / 0.3 / nc / (nc-nc)
Female / 0 / 0.4 / nc / (nc-nc) / Female / 0 / 0.2 / nc / (nc-nc)
Larynx / Testis
Male / 1 / 0.2 / nc / (nc-nc) / Male / 0 / 0.1 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc)
Leukemia / Thyroid
Male / 0 / 0.5 / nc / (nc-nc) / Male / 0 / 0.3 / nc / (nc-nc)
Female / 0 / 0.4 / nc / (nc-nc) / Female / 0 / 1.0 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 1 / 0.4 / nc / (nc-nc)
Female / 0 / 0.2 / nc / (nc-nc) / Female / 2 / 1.3 / nc / (nc-nc)
Lung and Bronchus / All Sites / Types
Male / 0 / 2.2 / nc / (nc-nc) / Male / 12 / 16.1 / 74.5 / (38.5-130.2)
Female / 0 / 2.4 / nc / (nc-nc) / Female / 8 / 18.3 / 43.8 / (18.8-86.2)
Obs = observed case count; Exp = expected case count;
SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability;
nc = The SIR and 95% CI were not calculated when Obs < 5;
117
Gosnold
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 1 / 0.1 / nc / (nc-nc) / Male / 0 / 0.1 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 0 / 0.2 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 0 / 0.0 / nc / (nc-nc) / Male / 0 / 0.0 / nc / (nc-nc)
Female / 0 / 0.0 / nc / (nc-nc) / Female / 0 / 0.1 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.0 / nc / (nc-nc) / Male / 0 / 0.1 / nc / (nc-nc)
Female / 0 / 1.4 / nc / (nc-nc) / Female / 0 / 0.2 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 0 / 0.1 / nc / (nc-nc)
Female / 0 / 0.0 / nc / (nc-nc) / Female / 0 / 0.1 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 0 / 0.2 / nc / (nc-nc)
Female / 1 / 0.3 / nc / (nc-nc) / Female / 0 / 0.1 / nc / (nc-nc)
Esophagus / Pancreas
Male / 0 / 0.0 / nc / (nc-nc) / Male / 0 / 0.1 / nc / (nc-nc)
Female / 0 / 0.0 / nc / (nc-nc) / Female / 0 / 0.1 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 0 / 0.0 / nc / (nc-nc) / Male / 0 / 0.5 / nc / (nc-nc)
Female / 0 / 0.0 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 0 / 0.1 / nc / (nc-nc) / Male / 0 / 0.0 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 0 / 0.0 / nc / (nc-nc)
Larynx / Testis
Male / 0 / 0.0 / nc / (nc-nc) / Male / 0 / 0.0 / nc / (nc-nc)
Female / 0 / 0.0 / nc / (nc-nc)
Leukemia / Thyroid
Male / 0 / 0.1 / nc / (nc-nc) / Male / 0 / 0.0 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 0 / 0.2 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 0 / 0.0 / nc / (nc-nc)
Female / 0 / 0.0 / nc / (nc-nc) / Female / 0 / 0.4 / nc / (nc-nc)
Lung and Bronchus / All Sites / Types
Male / 0 / 0.2 / nc / (nc-nc) / Male / 1 / 1.9 / nc / (nc-nc)
Female / 0 / 0.7 / nc / (nc-nc) / Female / 1 / 4.6 / nc / (nc-nc)
Obs = observed case count; Exp = expected case count;
SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability;
nc = The SIR and 95% CI were not calculated when Obs < 5;
118
Grafton
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 18 / 15.3 / 117.8 / (69.8-186.2) / Male / 9 / 10.6 / 85.2 / (38.9-161.7)
Female / 4 / 5.2 / nc / (nc-nc) / Female / 10 / 8.6 / 116.7 / (55.9-214.6)
Brain and Other Nervous System / Multiple Myeloma
Male / 11 / 3.5 / 315.5 / (157.3-564.6) / Male / 4 / 3.2 / nc / (nc-nc)
Female / 4 / 2.7 / nc / (nc-nc) / Female / 1 / 2.4 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.5 / nc / (nc-nc) / Male / 4 / 9.5 / nc / (nc-nc)
Female / 80 / 65.9 / 121.3 / (96.2-151.0) / Female / 11 / 7.7 / 142.2 / (70.9-254.5)
Cervix Uteri / Oral Cavity & Pharynx
Male / 17 / 7.9 / 214.6 / (124.9-343.6)
Female / 2 / 2.5 / nc / (nc-nc) / Female / 3 / 3.3 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 14 / 17.6 / 79.4 / (43.3-133.1)
Female / 22 / 16.2 / 136.0 / (85.2-205.9) / Female / 6 / 5.7 / 104.4 / (38.1-227.2)
Esophagus / Pancreas
Male / 5 / 4.2 / 119.6 / (38.6-279.2) / Male / 4 / 5.5 / nc / (nc-nc)
Female / 0 / 1.0 / nc / (nc-nc) / Female / 4 / 5.2 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 0 / 1.4 / nc / (nc-nc) / Male / 59 / 52.4 / 112.6 / (85.7-145.3)
Female / 0 / 1.1 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 11 / 9.2 / 119.9 / (59.8-214.5) / Male / 1 / 3.7 / nc / (nc-nc)
Female / 5 / 5.1 / 98.9 / (31.9-230.9) / Female / 1 / 2.1 / nc / (nc-nc)
Larynx / Testis
Male / 6 / 2.5 / 243.6 / (89.0-530.3) / Male / 4 / 2.8 / nc / (nc-nc)
Female / 2 / 0.8 / nc / (nc-nc)
Leukemia / Thyroid
Male / 12 / 6.7 / 179.0 / (92.4-312.7) / Male / 7 / 4.6 / 152.6 / (61.2-314.5)
Female / 10 / 4.6 / 216.4 / (103.6-397.9) / Female / 13 / 13.9 / 93.4 / (49.7-159.7)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 6 / 5.8 / 103.5 / (37.8-225.3)
Female / 0 / 1.7 / nc / (nc-nc) / Female / 13 / 14.7 / 88.7 / (47.2-151.7)
Lung and Bronchus / All Sites / Types
Male / 34 / 27.4 / 123.9 / (85.8-173.1) / Male / 235 / 211.0 / 111.4 / (97.6-126.6)
Female / 35 / 28.5 / 122.7 / (85.5-170.7) / Female / 248 / 215.2 / 115.2 / (101.3-130.5)
Obs = observed case count; Exp = expected case count;
SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability;
nc = The SIR and 95% CI were not calculated when Obs < 5;
119
Granby
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 5 / 6.7 / 74.6 / (24.0-174.0) / Male / 1 / 4.4 / nc / (nc-nc)
Female / 3 / 2.8 / nc / (nc-nc) / Female / 3 / 4.0 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 3 / 1.3 / nc / (nc-nc) / Male / 0 / 1.4 / nc / (nc-nc)
Female / 1 / 1.2 / nc / (nc-nc) / Female / 0 / 1.3 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.2 / nc / (nc-nc) / Male / 6 / 3.9 / 154.7 / (56.5-336.7)
Female / 18 / 32.6 / 55.3 / (32.8-87.4) / Female / 3 / 4.0 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 1 / 3.2 / nc / (nc-nc)
Female / 1 / 1.1 / nc / (nc-nc) / Female / 1 / 1.7 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 9 / 7.2 / 124.4 / (56.8-236.1)
Female / 6 / 8.7 / 69.2 / (25.3-150.7) / Female / 5 / 2.9 / 174.8 / (56.3-407.9)
Esophagus / Pancreas
Male / 4 / 1.8 / nc / (nc-nc) / Male / 2 / 2.4 / nc / (nc-nc)
Female / 1 / 0.6 / nc / (nc-nc) / Female / 1 / 2.8 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 1 / 0.5 / nc / (nc-nc) / Male / 18 / 23.0 / 78.2 / (46.3-123.5)
Female / 0 / 0.4 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 3 / 3.7 / nc / (nc-nc) / Male / 2 / 1.6 / nc / (nc-nc)
Female / 4 / 2.5 / nc / (nc-nc) / Female / 0 / 1.1 / nc / (nc-nc)
Larynx / Testis
Male / 1 / 1.1 / nc / (nc-nc) / Male / 1 / 0.9 / nc / (nc-nc)
Female / 0 / 0.4 / nc / (nc-nc)
Leukemia / Thyroid
Male / 1 / 2.7 / nc / (nc-nc) / Male / 0 / 1.7 / nc / (nc-nc)
Female / 1 / 2.2 / nc / (nc-nc) / Female / 4 / 5.8 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 1 / 2.5 / nc / (nc-nc)
Female / 1 / 0.9 / nc / (nc-nc) / Female / 11 / 7.4 / 149.2 / (74.4-267.0)
Lung and Bronchus / All Sites / Types
Male / 13 / 11.9 / 109.2 / (58.1-186.8) / Male / 79 / 89.0 / 88.7 / (70.2-110.6)
Female / 13 / 14.7 / 88.5 / (47.1-151.3) / Female / 82 / 107.5 / 76.3 / (60.7-94.7)
Obs = observed case count; Exp = expected case count;
SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability;
nc = The SIR and 95% CI were not calculated when Obs < 5;
120
Granville
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 4 / 2.2 / nc / (nc-nc) / Male / 1 / 1.4 / nc / (nc-nc)
Female / 1 / 0.6 / nc / (nc-nc) / Female / 1 / 0.9 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 0 / 0.4 / nc / (nc-nc) / Male / 1 / 0.5 / nc / (nc-nc)
Female / 0 / 0.3 / nc / (nc-nc) / Female / 0 / 0.3 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.1 / nc / (nc-nc) / Male / 3 / 1.3 / nc / (nc-nc)
Female / 7 / 7.7 / 91.2 / (36.5-188.0) / Female / 0 / 0.9 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 2 / 1.1 / nc / (nc-nc)
Female / 0 / 0.2 / nc / (nc-nc) / Female / 0 / 0.4 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 3 / 2.4 / nc / (nc-nc)
Female / 2 / 1.8 / nc / (nc-nc) / Female / 1 / 0.7 / nc / (nc-nc)
Esophagus / Pancreas
Male / 0 / 0.6 / nc / (nc-nc) / Male / 0 / 0.8 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 0 / 0.6 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 0 / 0.1 / nc / (nc-nc) / Male / 10 / 8.4 / 118.9 / (56.9-218.7)
Female / 0 / 0.1 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 3 / 1.3 / nc / (nc-nc) / Male / 0 / 0.5 / nc / (nc-nc)
Female / 0 / 0.6 / nc / (nc-nc) / Female / 0 / 0.2 / nc / (nc-nc)
Larynx / Testis
Male / 0 / 0.4 / nc / (nc-nc) / Male / 0 / 0.2 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc)
Leukemia / Thyroid
Male / 1 / 0.9 / nc / (nc-nc) / Male / 1 / 0.5 / nc / (nc-nc)
Female / 0 / 0.5 / nc / (nc-nc) / Female / 4 / 1.3 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 0 / 0.8 / nc / (nc-nc)
Female / 0 / 0.2 / nc / (nc-nc) / Female / 4 / 1.8 / nc / (nc-nc)
Lung and Bronchus / All Sites / Types
Male / 2 / 4.1 / nc / (nc-nc) / Male / 32 / 30.1 / 106.1 / (72.6-149.9)
Female / 5 / 3.5 / 141.4 / (45.6-330.0) / Female / 26 / 24.7 / 105.1 / (68.6-154.0)
Obs = observed case count; Exp = expected case count;
SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability;
nc = The SIR and 95% CI were not calculated when Obs < 5;
121
Great Barrington
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 12 / 8.4 / 142.7 / (73.6-249.2) / Male / 9 / 5.2 / 172.4 / (78.7-327.3)
Female / 9 / 3.9 / 230.8 / (105.3-438.1) / Female / 3 / 4.7 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 2 / 1.5 / nc / (nc-nc) / Male / 2 / 1.6 / nc / (nc-nc)
Female / 1 / 1.4 / nc / (nc-nc) / Female / 1 / 1.7 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 1 / 0.3 / nc / (nc-nc) / Male / 2 / 4.7 / nc / (nc-nc)
Female / 39 / 36.8 / 106.1 / (75.5-145.1) / Female / 5 / 5.1 / 98.4 / (31.7-229.7)
Cervix Uteri / Oral Cavity & Pharynx
Male / 3 / 3.6 / nc / (nc-nc)
Female / 2 / 1.1 / nc / (nc-nc) / Female / 2 / 2.1 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 8 / 8.9 / 90.2 / (38.8-177.8)
Female / 10 / 11.5 / 87.2 / (41.7-160.4) / Female / 3 / 3.4 / nc / (nc-nc)
Esophagus / Pancreas
Male / 3 / 2.1 / nc / (nc-nc) / Male / 0 / 2.9 / nc / (nc-nc)
Female / 0 / 0.7 / nc / (nc-nc) / Female / 1 / 4.0 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 0 / 0.6 / nc / (nc-nc) / Male / 32 / 25.3 / 126.7 / (86.6-178.9)
Female / 0 / 0.5 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 4 / 4.3 / nc / (nc-nc) / Male / 3 / 1.9 / nc / (nc-nc)
Female / 2 / 3.0 / nc / (nc-nc) / Female / 0 / 1.5 / nc / (nc-nc)
Larynx / Testis
Male / 3 / 1.2 / nc / (nc-nc) / Male / 1 / 1.1 / nc / (nc-nc)
Female / 0 / 0.5 / nc / (nc-nc)
Leukemia / Thyroid
Male / 3 / 3.3 / nc / (nc-nc) / Male / 0 / 1.9 / nc / (nc-nc)
Female / 4 / 2.9 / nc / (nc-nc) / Female / 9 / 5.7 / 158.4 / (72.3-300.6)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 4 / 2.7 / nc / (nc-nc)
Female / 1 / 1.2 / nc / (nc-nc) / Female / 7 / 8.4 / 83.1 / (33.3-171.2)
Lung and Bronchus / All Sites / Types
Male / 14 / 14.3 / 97.9 / (53.5-164.2) / Male / 115 / 104.7 / 109.9 / (90.7-131.9)
Female / 21 / 19.7 / 106.5 / (65.9-162.9) / Female / 131 / 131.0 / 100.0 / (83.6-118.7)
Obs = observed case count; Exp = expected case count;
SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability;
nc = The SIR and 95% CI were not calculated when Obs < 5;
122
Greenfield
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 19 / 20.2 / 94.0 / (56.6-146.8) / Male / 13 / 13.0 / 100.1 / (53.2-171.1)
Female / 5 / 8.0 / 62.5 / (20.1-145.9) / Female / 5 / 10.7 / 46.6 / (15.0-108.8)
Brain and Other Nervous System / Multiple Myeloma
Male / 5 / 3.8 / 130.4 / (42.0-304.4) / Male / 4 / 4.1 / nc / (nc-nc)
Female / 7 / 3.3 / 214.9 / (86.1-442.9) / Female / 3 / 3.5 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.7 / nc / (nc-nc) / Male / 5 / 11.5 / 43.4 / (14.0-101.3)
Female / 74 / 82.8 / 89.4 / (70.2-112.2) / Female / 13 / 10.8 / 119.9 / (63.8-205.1)
Cervix Uteri / Oral Cavity & Pharynx
Male / 9 / 9.4 / 95.5 / (43.6-181.3)
Female / 3 / 2.7 / nc / (nc-nc) / Female / 3 / 4.5 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 28 / 21.7 / 129.2 / (85.8-186.7)
Female / 26 / 24.3 / 107.0 / (69.9-156.7) / Female / 9 / 7.4 / 120.9 / (55.2-229.5)
Esophagus / Pancreas
Male / 3 / 5.4 / nc / (nc-nc) / Male / 7 / 7.1 / 97.9 / (39.2-201.8)
Female / 1 / 1.5 / nc / (nc-nc) / Female / 5 / 8.1 / 61.5 / (19.8-143.6)
Hodgkin Lymphoma / Prostate
Male / 6 / 1.5 / 412.8 / (150.8-898.6) / Male / 46 / 69.1 / 66.6 / (48.7-88.8)
Female / 3 / 1.2 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 6 / 11.0 / 54.6 / (20.0-118.9) / Male / 3 / 4.8 / nc / (nc-nc)
Female / 6 / 6.7 / 90.2 / (32.9-196.3) / Female / 3 / 3.2 / nc / (nc-nc)
Larynx / Testis
Male / 2 / 3.2 / nc / (nc-nc) / Male / 1 / 2.7 / nc / (nc-nc)
Female / 1 / 1.0 / nc / (nc-nc)
Leukemia / Thyroid
Male / 3 / 8.0 / nc / (nc-nc) / Male / 1 / 5.0 / nc / (nc-nc)
Female / 6 / 6.4 / 94.4 / (34.5-205.5) / Female / 3 / 14.7 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 5 / 7.2 / 69.1 / (22.3-161.2)
Female / 5 / 2.5 / 203.8 / (65.7-475.5) / Female / 21 / 18.7 / 112.6 / (69.6-172.1)
Lung and Bronchus / All Sites / Types
Male / 33 / 36.2 / 91.1 / (62.7-127.9) / Male / 222 / 266.3 / 83.4 / (72.7-95.1)
Female / 44 / 40.4 / 109.0 / (79.2-146.3) / Female / 273 / 286.4 / 95.3 / (84.4-107.3)
Obs = observed case count; Exp = expected case count;
SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability;
nc = The SIR and 95% CI were not calculated when Obs < 5;
123
Groton
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 12 / 9.5 / 125.8 / (64.9-219.8) / Male / 3 / 6.9 / nc / (nc-nc)
Female / 1 / 3.1 / nc / (nc-nc) / Female / 2 / 5.4 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 2 / 2.2 / nc / (nc-nc) / Male / 3 / 2.1 / nc / (nc-nc)
Female / 1 / 1.7 / nc / (nc-nc) / Female / 2 / 1.5 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.4 / nc / (nc-nc) / Male / 4 / 6.2 / nc / (nc-nc)
Female / 38 / 45.1 / 84.3 / (59.6-115.6) / Female / 4 / 4.8 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 5 / 5.6 / 89.1 / (28.7-208.0)
Female / 1 / 1.6 / nc / (nc-nc) / Female / 1 / 2.2 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 16 / 11.4 / 140.8 / (80.4-228.7)
Female / 9 / 9.8 / 91.5 / (41.7-173.6) / Female / 2 / 3.8 / nc / (nc-nc)
Esophagus / Pancreas
Male / 1 / 2.9 / nc / (nc-nc) / Male / 3 / 3.6 / nc / (nc-nc)
Female / 0 / 0.6 / nc / (nc-nc) / Female / 2 / 3.0 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 0 / 0.9 / nc / (nc-nc) / Male / 31 / 38.4 / 80.6 / (54.8-114.5)
Female / 0 / 0.6 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 4 / 6.3 / nc / (nc-nc) / Male / 2 / 2.4 / nc / (nc-nc)
Female / 1 / 3.3 / nc / (nc-nc) / Female / 3 / 1.2 / nc / (nc-nc)
Larynx / Testis
Male / 2 / 1.7 / nc / (nc-nc) / Male / 7 / 1.4 / 486.1 / (194.7-1001.6)
Female / 0 / 0.5 / nc / (nc-nc)
Leukemia / Thyroid
Male / 5 / 4.2 / 120.0 / (38.7-280.1) / Male / 4 / 3.1 / nc / (nc-nc)
Female / 1 / 2.7 / nc / (nc-nc) / Female / 7 / 8.8 / 79.4 / (31.8-163.5)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 2 / 4.1 / nc / (nc-nc)
Female / 2 / 1.1 / nc / (nc-nc) / Female / 10 / 10.3 / 97.1 / (46.5-178.7)
Lung and Bronchus / All Sites / Types
Male / 11 / 18.1 / 60.8 / (30.3-108.7) / Male / 128 / 141.8 / 90.3 / (75.3-107.4)
Female / 10 / 17.9 / 56.0 / (26.8-103.0) / Female / 104 / 138.7 / 75.0 / (61.3-90.9)
Obs = observed case count; Exp = expected case count;
SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability;
nc = The SIR and 95% CI were not calculated when Obs < 5;
124
Groveland
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 8 / 8.0 / 99.9 / (43.0-196.9) / Male / 6 / 5.1 / 117.1 / (42.8-254.9)
Female / 2 / 2.7 / nc / (nc-nc) / Female / 11 / 3.9 / 281.5 / (140.3-503.7)
Brain and Other Nervous System / Multiple Myeloma
Male / 1 / 1.5 / nc / (nc-nc) / Male / 1 / 1.6 / nc / (nc-nc)
Female / 1 / 1.2 / nc / (nc-nc) / Female / 1 / 1.3 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.3 / nc / (nc-nc) / Male / 8 / 4.6 / 174.3 / (75.1-343.5)
Female / 39 / 32.6 / 119.5 / (85.0-163.4) / Female / 6 / 3.9 / 155.2 / (56.7-337.8)
Cervix Uteri / Oral Cavity & Pharynx
Male / 3 / 3.7 / nc / (nc-nc)
Female / 2 / 1.0 / nc / (nc-nc) / Female / 2 / 1.7 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 4 / 8.8 / nc / (nc-nc)
Female / 9 / 8.0 / 112.6 / (51.4-213.8) / Female / 3 / 2.8 / nc / (nc-nc)
Esophagus / Pancreas
Male / 4 / 2.1 / nc / (nc-nc) / Male / 3 / 2.8 / nc / (nc-nc)
Female / 0 / 0.5 / nc / (nc-nc) / Female / 4 / 2.7 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 0 / 0.6 / nc / (nc-nc) / Male / 24 / 26.9 / 89.3 / (57.2-132.9)
Female / 0 / 0.4 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 3 / 4.4 / nc / (nc-nc) / Male / 2 / 1.9 / nc / (nc-nc)
Female / 3 / 2.5 / nc / (nc-nc) / Female / 4 / 1.0 / nc / (nc-nc)
Larynx / Testis
Male / 2 / 1.3 / nc / (nc-nc) / Male / 1 / 1.0 / nc / (nc-nc)
Female / 0 / 0.4 / nc / (nc-nc)
Leukemia / Thyroid
Male / 2 / 3.1 / nc / (nc-nc) / Male / 1 / 1.9 / nc / (nc-nc)
Female / 2 / 2.2 / nc / (nc-nc) / Female / 10 / 5.6 / 179.8 / (86.1-330.7)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 0 / 2.8 / nc / (nc-nc)
Female / 1 / 0.9 / nc / (nc-nc) / Female / 4 / 7.8 / nc / (nc-nc)
Lung and Bronchus / All Sites / Types
Male / 11 / 14.5 / 76.1 / (37.9-136.1) / Male / 90 / 104.9 / 85.8 / (69.0-105.4)
Female / 17 / 15.1 / 112.8 / (65.7-180.6) / Female / 125 / 106.1 / 117.8 / (98.1-140.4)
Obs = observed case count; Exp = expected case count;
SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability;
nc = The SIR and 95% CI were not calculated when Obs < 5;
125
Hadley
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 3 / 6.8 / nc / (nc-nc) / Male / 1 / 4.2 / nc / (nc-nc)
Female / 6 / 3.2 / 187.4 / (68.4-408.0) / Female / 3 / 3.8 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 0 / 1.2 / nc / (nc-nc) / Male / 2 / 1.3 / nc / (nc-nc)
Female / 0 / 1.2 / nc / (nc-nc) / Female / 0 / 1.4 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.2 / nc / (nc-nc) / Male / 7 / 3.7 / 188.3 / (75.4-388.0)
Female / 28 / 29.4 / 95.2 / (63.3-137.6) / Female / 7 / 4.1 / 170.1 / (68.1-350.4)
Cervix Uteri / Oral Cavity & Pharynx
Male / 7 / 2.9 / 240.6 / (96.4-495.7)
Female / 1 / 0.9 / nc / (nc-nc) / Female / 0 / 1.7 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 5 / 7.0 / 70.9 / (22.9-165.6)
Female / 10 / 9.2 / 108.9 / (52.1-200.3) / Female / 2 / 2.7 / nc / (nc-nc)
Esophagus / Pancreas
Male / 1 / 1.7 / nc / (nc-nc) / Male / 3 / 2.3 / nc / (nc-nc)
Female / 0 / 0.6 / nc / (nc-nc) / Female / 2 / 3.2 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 0 / 0.5 / nc / (nc-nc) / Male / 19 / 22.1 / 86.1 / (51.8-134.5)
Female / 0 / 0.4 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 2 / 3.5 / nc / (nc-nc) / Male / 2 / 1.6 / nc / (nc-nc)
Female / 2 / 2.5 / nc / (nc-nc) / Female / 2 / 1.2 / nc / (nc-nc)
Larynx / Testis
Male / 0 / 1.0 / nc / (nc-nc) / Male / 0 / 0.8 / nc / (nc-nc)
Female / 0 / 0.4 / nc / (nc-nc)
Leukemia / Thyroid
Male / 3 / 2.6 / nc / (nc-nc) / Male / 1 / 1.5 / nc / (nc-nc)
Female / 3 / 2.4 / nc / (nc-nc) / Female / 2 / 4.4 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 0 / 2.2 / nc / (nc-nc)
Female / 1 / 0.9 / nc / (nc-nc) / Female / 9 / 6.9 / 131.3 / (59.9-249.2)
Lung and Bronchus / All Sites / Types
Male / 6 / 12.1 / 49.7 / (18.1-108.1) / Male / 71 / 85.9 / 82.6 / (64.5-104.2)
Female / 9 / 16.2 / 55.7 / (25.4-105.8) / Female / 92 / 105.6 / 87.1 / (70.2-106.8)
Obs = observed case count; Exp = expected case count;